505 (b) (2) approvals in May 2025

There are three 505(b)(2) NDAs approved by the USFDA and one NDA that received tentative approval from the USFDA in May 2025. The details are as follows.


More details can also be found in the API and IP newsletter published by us. 


Comments

Post a Comment

Popular posts from this blog

AI Act Guide Version 1.1 – September 2025

AI Act Guide Version 1.1 – September 2025 The "AI Act Guide" offers an overview of the main aspects of the AI Act, a legal framework that regulates Artificial Intelligence (AI) within the European Union (EU). The guide aims to provide insights into the rules and regulations for organizations that develop, deploy, or use AI systems. It highlights that the legal text of the AI Act always overrides other considerations and encourages users to give feedback to improve future versions of the guide. Scope and Objectives of the AI Act: The AI Act aims to ensure the responsible development and use of AI, protecting the safety, health, and fundamental rights of individuals. It applies to businesses, governments, and other organisations operating within the EU. The regulations are being introduced in phases, with some prohibitions already in effect. Key Steps for Organisations: The guide outlines a four-step process for organisations to determine how the AI Act applies to them...
Read more

Summary of FDA inspection of Hetero Labs Unit-X

Image
General Information: Facility: Hetero Labs Limited, Unit-IX, located in Narasapuram Village, Andhra Pradesh, India. Inspection Dates: 09/19-26/2025. Type of Establishment: API (Active Pharmaceutical Ingredient) Manufacturer. Key Observations: 1. Unregistered Testing Laboratory: The facility used an unregistered testing laboratory for API testing, which was not referenced in their Drug Master Files (DMFs). This laboratory was located away from the main facility. Finished API samples with matching batch numbers and dates were discovered, indicating collaboration with the unregistered lab. The firm did not have a quality agreement established with this unregistered testing facility conducting analysis on products manufactured by your firm. Multiple examples of API intermediate samples were found at the unregistered testing laboratory. Numerous uncontrolled notebook pages containing analytical test results for APIs and API intermediates manufactured at this facility were found in the ...
Read more

India Mandates Digital Monitoring of High-Risk Solvents to Ensure the Safety of Cough Syrups.

Image
The Directorate General of Health Services has issued a directive regarding the monitoring of high-risk solvents in the pharmaceutical supply chain due to recent reports of cough syrup contamination with DEG.  A Digital Monitoring System has been established on the ONDLS ( Online National Drugs Licensing System  )  portal for this purpose.  All state and UT drug controllers are requested to direct pharma-grade solvent manufacturers to obtain manufacturing licenses through the ONDLS portal. Manufacturers already holding licenses must register and submit data.  Solvent manufacturers must also upload batch details, including quantity and vendor information, to the ONDLS portal. Compliance with these directions is mandatory to ensure no non-compliant batches are available in the market. Table of High-Risk Solvents News from DrugsControl Media Services: Here The USFDA has also taken note of issues arising in India and published the following information on its websi...
Read more